[CAS NO. 86329-79-5] Cefodizime sodium
PRODUCTS SPECIFICATIONS [86329-79-5]
DESCRIPTION [86329-79-5]
Overview
| MDL | MFCD00897059 |
|---|---|
| Molecular Weight | 628.63 |
| Molecular Formula | C20H18N6Na2O7S4 |
| SMILES | O=C(C(N12)=C(CSC3=NC(C)=C(CC(O[Na])=O)S3)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O[Na] |
Summary
Cefodizime sodium is a third generation cephalosporin antibiotic with a broad spectrum of antibacterial activity. Cefodizime sodium has no renal toxic effect, good tolerance and immune regulation activity, and can be used for the research of severe infections of the respiratory and urinary tracts [1] [2] .
IC50 & Target
Bacterial [1]
In Vitro
Enterobacteriaceae including
Escherichia coli
,
Klebsiella pneumoniae
,
Morganella morgan ii
,
Proteus mirabilis
,
Proteus vulgaris
,
Shigella sonnei
,
Yersinia enterocolitica
and
Salmonella
species are all consistently sensitive to Cefodizime in vitro. Cefodizime has marginal but variable inhibitory activity against
Citrobacter
species including
Citrobacter freundii
, and
Serratia marcescens
. Cefodizime inhibits other Gram-negative bacteria including
Haemophilus irifluenzae
,
Moraxella catarrhalis
,
Neisseria gonorrhoeae
and
Neisseria meningitidis
[1]
.
Cefodizime is a bactericidal antibiotic having high affinity for penicillin-binding proteins lA/B, 2 and 3 of
E. coli
. The in vitro concentrations of Cefodizime resulting in bactericidal activity against susceptible strains of Gram-positive and Gram-negative bacteria are generally similar to the minimum inhibitory concentrations
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
In experimentally-induced K. pneumoniae respiratory tract infections in mice, Cefodizime has activity comparable to Cefotaxime and Ceftazidime, and greater than that of Cefoperazone, Latamoxef, Cefuroxime or cefazolin for 8 hours after a single subcutaneous dose of 50 mg/kg. However, unlike these cephalosporins, Cefodizime continues to demonstrate pronounced bactericidal activity for at least 48 hours after a single injection. Complete bacterial clearance from the lung is achieved within 48 hours in 50% of the mice although Cefodizime is no longer detectable in the serum [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 100 mg/mL ( 159.08 mM ; Need ultrasonic)
DMSO : 62.5 mg/mL ( 99.42 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.5908 mL | 7.9538 mL | 15.9076 mL |
| 5 mM | 0.3182 mL | 1.5908 mL | 3.1815 mL |
| 10 mM | 0.1591 mL | 0.7954 mL | 1.5908 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (159.08 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.31 mM); Clear solution
References
- [1] Barradell LB, et al. Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1992 Nov;44(5):800-34.
- [2] Hu T, et al. Probing the interaction of cefodizime with human serum albumin using multi-spectroscopic and molecular docking techniques. J Pharm Biomed Anal. 2015 Mar 25;107:325-32.
Synonyms